BL-M24D1
Phase 1Small molecule
BL-M24D1 is one of 135 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 1.
4
Indications
4
Total Trials
4
Active Trials
134
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
414 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Adstiladrin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
AK112
SSummit Therapeutics
Phase 3
SI-B001
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
Remeron
OOrganon and Co
Preclinical
BL-M24D1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 1
Treatment
GSKPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
PD-1 Inhibitors
BBioNTech US Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Gastrointestinal Tumors1 trial
Head and Neck Squamous Cell Carcinoma1 trial
Non-Small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BL-M24D1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details